Table I.
Clinicopathological characteristic | n | % |
---|---|---|
All patients | 331 | 100 |
Follow-up, months | ||
Median (range) | 98.97 | |
(2.63–120.47) | ||
Age, years | ||
Median (range) | 55 (23–86) | |
Sex | ||
Female | 97 | 29.3 |
Male | 234 | 70.7 |
ECOG PS | ||
0 | 223 | 67.4 |
1 | 67 | 20.2 |
2 | 32 | 9.7 |
3 | 9 | 2.7 |
Fuhrman nuclear grade | ||
1 | 36 | 10.9 |
2 | 247 | 74.6 |
3 | 45 | 13.6 |
4 | 3 | 0.9 |
Necrosis | ||
Absent | 287 | 86.6 |
Present | 44 | 13.3 |
T classification | ||
T1 | 215 | 65.0 |
T2 | 25 | 7.6 |
T3 | 87 | 26.3 |
T4 | 4 | 1.2 |
N classification | ||
Nx | 283 | 85.5 |
N0 | 46 | 13.9 |
N1 | 2 | 0.6 |
Distant metastasis | ||
No | 315 | 95.2 |
Yes | 16 | 4.8 |
TNM stage | ||
I | 209 | 63.1 |
II | 20 | 6.0 |
III | 83 | 25.1 |
IV | 19 | 5.7 |
Surgery | ||
Nephron-sparing (open) | 37 | 11.2 |
Nephron-sparing (laparoscopic) | 1 | 0.3 |
Radical nephrectomy (open) | 268 | 81.0 |
Radical nephrectomy (laparoscopic) | 25 | 7.5 |
ECOG PS, Eastern Cooperative Oncology Group performance status.